You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Point-of-care immunoassay for early diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: R

    Project Summary Pertussis is rapidly re emerging as a serious public health threat in the United StatesDespite high vaccine coverage nationallyannual reported cases in the U Shave been increasing recentlywith ayear high ofinMoreoverreported cases represent a large underestimate of pertussis infectionsDiagnosis of early pertussiscatarrhal stageprior to paroxysmal coughis particularly challenging be ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Point of care immunoassay for rapid diagnosis of tinea capitis

    SBC: DXDISCOVERY INC            Topic: NIBIB

    Tinea capitis scalp ringworm is a fungal dermatophyte infection of scalp hair follicles that afflicts of the U S pediatric population Tinea capitis is a major health care disparity because it occurs predominantly among individuals with a disadvantaged socioeconomic background and sub Saharan African descent Diagnosis of tinea capitis is currently dependent on culture and microscopy Both ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System

    SBC: ABT Molecular Imaging            Topic: 102

    DESCRIPTION provided by applicant Worldwide a person dies from cancer every seconds Positron emission tomography PET is an effective tool that is critical in diagnosing cancer and monitoring treatment efficacy PET imaging relies on use of short lived radioisotopes Commercial distribution of the most commonly used radio tracer F FDG has resulted in patient population coverage in ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Multi Source E Beam kV X Ray Tube for Image Guided Radiotheraphy

    SBC: Telesecurity Sciences, Inc.            Topic: 102

    DESCRIPTION provided by applicant This project will develop a commercial product that will enable for the first time realtime tumor tracking during radiotherapy at an attractive price point and with minimal interference with standard clinical practice The key novel technology is an optimized multi source X ray tube with focal spots that is placed below the multi leaf collimator MLC of a r ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer

    SBC: ACTORIUS PHARMACEUTICALS, LLC            Topic: 100

    DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government